Ares Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH and a developer of pioneering solutions for the detection of genetic resistances in pathogens, today announced that the project "GEAR - Predicting Antibiotic Resistances with Genetic Data" has been awarded in the competition "Landmarks in…

Every year, some 25,000 people die in the European Union from antibiotic-resistant, hard to treat bacteria. Although there are diagnostic methods in place to recognize such resistances in advance, these are typically very time-consuming. Researchers from the Center for Bioinformatics at Saarland Uni…

- Clinical study to test more than 400 patient samples
- Follows successful completion of analytical CE Performance Evaluation in more than 400 cartridge runs
- Expected results and product launch in spring 2015

Curetis AG, a developer of next-level molecular diagnostic solutions, today announced the…

- Multiple Unyvero product launches planned for 2015
- Clinical trial aimed at US FDA clearance of Unyvero adapted to reflect most recent FDA guideline issued in Q3-2014

Curetis AG, a developer of next-level molecular diagnostic solutions, announced on Feb. 17, 2015, the presentation of its product ra…

- Curetis wins new investors QIAGEN and LSP-HEF, committing EUR 7 million
- Curetis well financed into 2017

Curetis AG, a developer of next-level molecular diagnostic solutions, today announced it has closed a EUR 14.5 million extension of its Series B financing round, which was originally led by HBM…

- Successful completion of CE performance evaluation study covering more than 400 patient samples
- Sales and Marketing Program Underway in Germany, Austria and Switzerland

Curetis AG, a developer of next-level molecular diagnostic solutions, today announced that it has launched its new Unyvero™ i6…

Curetis AG, ein Unternehmen, das zukunftsweisende diagnostische Lösungen entwickelt, hat heute positive klinische Daten einer unabhängigen Evaluierungsstudie der Unyvero™ P50 Lungenentzündungskartusche bekannt gegeben. Die Ergebnisse der Studie aus der Abteilung für Medizinische Mikrobiologie…

Die Curetis AG aus Holzgerlingen bei Böblingen entwickelt Analysegeräte zum Nachweis von Infektionskrankheiten und Antibiotika-Resistenzen. Die Miniaturlabore liefern in wenigen Stunden die Ergebnisse einer DNA-Analyse. Ärzte, die bisher bis zu vier Tage auf eine Diagnose warten mussten, können…